心臓血管薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年

心臓血管薬市場 - レポートの範囲

世界の心臓血管薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の心臓血管薬の収益を提供します。 2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間の市場を分析します。このレポートは、2023年から2031年までの世界の心臓血管薬市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、パーキンソン病治療薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界の心臓血管薬市場の競合情勢を詳しく調査しています。世界の心臓血管薬市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の心臓血管薬市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

• イントロダクション
• 概要
• 市場力学
• 世界市場の分析と予測、2017年～2031年

第5章 重要な洞察

• パイプライン分析
• 主要製品/ブランド分析
• 主な合併と買収
• COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：薬剤クラス別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：薬剤クラス別、2017年～2031年
  • レニン-アンジオテンシン系遮断薬
    • ACE阻害剤
    • アンジオテンシン受容体遮断薬
  • ベータブロッカー
  • 利尿薬
  • 抗凝固剤
    • 抗凝固剤
    • 血小板凝集阻害剤
  • 高脂血症治療薬
  • その他の降圧剤
  • カルシウムチャネルブロッカー
  • その他
• 市場魅力分析：薬剤クラス別

第7章 世界市場の分析と予測：適応症別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：指標別、2017年～2031年
  • 高血圧
  • 高脂血症
  • 冠動脈疾患
  • 末梢動脈疾患
  • 不整脈
  • その他
• 市場魅力度分析：適応症別

第8章 世界市場の分析と予測：流通チャネル別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：流通チャネル別、2017年～2031年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 市場魅力度分析：流通チャネル別

第9章 世界市場の分析と予測：地域別

• 主な調査結果
• 市場金額予測：地域別、2017年～2031年
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
• 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

List of Tables

• Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
• Table 03: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 04: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
• Table 05: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
• Table 06: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 07: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
• Table 08: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 09: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 10: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 11: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
• Table 12: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 13: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 14: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 15: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
• Table 16: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 17: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 18: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 19: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
• Table 20: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 21: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 22: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
• Table 23: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
• Table 24: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

• Figure 01: Global Cardiovascular Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
• Figure 02: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Drug Class, 2022
• Figure 03: Global Cardiovascular Drugs Market Value Share, by Drug Class, 2022
• Figure 04: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Indication, 2022
• Figure 05: Global Cardiovascular Drugs Market Value Share, by Indication, 2022
• Figure 06: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
• Figure 07: Global Cardiovascular Drugs Market Value Share, by Distribution Channel, 2022
• Figure 08: Global Cardiovascular Drugs Market Value Share, by Region, 2022
• Figure 09: Global Cardiovascular Drugs Market Value (US$ Mn) Forecast, 2023-2031
• Figure 10: Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
• Figure 11: Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
• Figure 12: Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
• Figure 13: Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
• Figure 14: Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 15: Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 16: Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2022 and 2031
• Figure 17: Global Cardiovascular Drugs Market Attractiveness Analysis, by Region, 2022-2031
• Figure 18: North America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 19: North America Cardiovascular Drugs Market Attractiveness Analysis, by Country, 2023-2031
• Figure 20: North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2022 and 2031
• Figure 21: North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
• Figure 22: North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
• Figure 23: North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 24: North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
• Figure 25: North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
• Figure 26: North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 27: Europe Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 28: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 29: Europe Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 30: Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
• Figure 31: Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
• Figure 32: Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 33: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
• Figure 34: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
• Figure 35: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 36: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 37: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 38: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 39: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
• Figure 40: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
• Figure 41: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 42: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
• Figure 43: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
• Figure 44: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 45: Latin America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 46: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 47: Latin America Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 48: Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
• Figure 49: Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
• Figure 50: Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 51: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
• Figure 52: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
• Figure 53: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 54: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 55: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 56: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 57: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
• Figure 58: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
• Figure 59: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 60: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
• Figure 61: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
• Figure 62: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Cardiovascular Drugs Market - Scope of Report

TMR's report on the global Parkinson's disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Parkinson's disease therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Parkinson's disease therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Parkinson's disease therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Parkinson's disease therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Parkinson's disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Parkinson's disease therapeutics market.

The report delves into the competitive landscape of the global Parkinson's disease therapeutics market. Key players operating in the global Parkinson's disease therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Parkinson's disease therapeutics market profiled in this report.

Key Questions Answered in Global Parkinson's disease therapeutics Market Report:

• What is the sales/revenue generated by Parkinson's disease therapeutics across all regions during the forecast period?
• What are the opportunities in the global Parkinson's disease therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cardiovascular Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global Parkinson's disease therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Parkinson's disease therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Parkinson's disease therapeutics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cardiovascular Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Cardiovascular Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Class, 2017-2031
  • 6.3.1. Renin-Angiotensin System Blockers
    • 6.3.1.1. ACE Inhibitors
    • 6.3.1.2. Angiotensin Receptor Blockers
  • 6.3.2. Beta Blockers
  • 6.3.3. Diuretics
  • 6.3.4. Anti-Clotting Agents
    • 6.3.4.1. Anti-Coagulants
    • 6.3.4.2. Platelet Aggregation Inhibitors
  • 6.3.5. Antihyperlipidemics
  • 6.3.6. Other Antihypertensive
  • 6.3.7. Calcium Channel Blockers
  • 6.3.8. Others
• 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Cardiovascular Drugs Market Analysis and Forecast, by Indication

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Indication, 2017-2031
  • 7.3.1. Hypertension
  • 7.3.2. Hyperlipidemia
  • 7.3.3. Coronary Artery Disease
  • 7.3.4. Peripheral Artery Disease
  • 7.3.5. Arrhythmia
  • 7.3.6. Others
• 7.4. Market Attractiveness Analysis, by Indication

8. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 8.3.1. Hospital Pharmacy
  • 8.3.2. Retail Pharmacy
  • 8.3.3. Online Pharmacy
• 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Cardiovascular Drugs Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2017-2031
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Cardiovascular Drugs Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Drug Class, 2017-2031
  • 10.3.1. Renin-Angiotensin System Blockers
    • 10.3.1.1. ACE Inhibitors
    • 10.3.1.2. Angiotensin Receptor Blockers
  • 10.3.2. Beta Blockers
  • 10.3.3. Diuretics
  • 10.3.4. Anti-Clotting Agents
    • 10.3.4.1. Anti-Coagulants
    • 10.3.4.2. Platelet Aggregation Inhibitors
  • 10.3.5. Antihyperlipidemics
  • 10.3.6. Other Antihypertensive
  • 10.3.7. Calcium Channel Blockers
  • 10.3.8. Others
• 10.4. Market Value Forecast, by Indication, 2017-2031
  • 10.4.1. Hypertension
  • 10.4.2. Hyperlipidemia
  • 10.4.3. Coronary Artery Disease
  • 10.4.4. Peripheral Artery Disease
  • 10.4.5. Arrhythmia
  • 10.4.6. Others
• 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.5.1. Hospital Pharmacy
  • 10.5.2. Retail Pharmacy
  • 10.5.3. Online Pharmacy
• 10.6. Market Value Forecast, by Country, 2017-2031
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Drug Class
  • 10.7.2. By Indication
  • 10.7.3. By Distribution Channel
  • 10.7.4. By Country

11. Europe Cardiovascular Drugs Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Drug Class, 2017-2031
  • 11.3.1. Renin-Angiotensin System Blockers
    • 11.3.1.1. ACE Inhibitors
    • 11.3.1.2. Angiotensin Receptor Blockers
  • 11.3.2. Beta Blockers
  • 11.3.3. Diuretics
  • 11.3.4. Anti-Clotting Agents
    • 11.3.4.1. Anti-Coagulants
    • 11.3.4.2. Platelet Aggregation Inhibitors
  • 11.3.5. Antihyperlipidemics
  • 11.3.6. Other Antihypertensive
  • 11.3.7. Calcium Channel Blockers
  • 11.3.8. Others
• 11.4. Market Value Forecast, by Indication, 2017-2031
  • 11.4.1. Hypertension
  • 11.4.2. Hyperlipidemia
  • 11.4.3. Coronary Artery Disease
  • 11.4.4. Peripheral Artery Disease
  • 11.4.5. Arrhythmia
  • 11.4.6. Others
• 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.5.1. Hospital Pharmacy
  • 11.5.2. Retail Pharmacy
  • 11.5.3. Online Pharmacy
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Drug Class
  • 11.7.2. By Indication
  • 11.7.3. By Distribution Channel
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Drug Class, 2017-2031
  • 12.3.1. Renin-Angiotensin System Blockers
    • 12.3.1.1. ACE Inhibitors
    • 12.3.1.2. Angiotensin Receptor Blockers
  • 12.3.2. Beta Blockers
  • 12.3.3. Diuretics
  • 12.3.4. Anti-Clotting Agents
    • 12.3.4.1. Anti-Coagulants
    • 12.3.4.2. Platelet Aggregation Inhibitors
  • 12.3.5. Antihyperlipidemics
  • 12.3.6. Other Antihypertensive
  • 12.3.7. Calcium Channel Blockers
  • 12.3.8. Others
• 12.4. Market Value Forecast, by Indication, 2017-2031
  • 12.4.1. Hypertension
  • 12.4.2. Hyperlipidemia
  • 12.4.3. Coronary Artery Disease
  • 12.4.4. Peripheral Artery Disease
  • 12.4.5. Arrhythmia
  • 12.4.6. Others
• 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.5.1. Hospital Pharmacy
  • 12.5.2. Retail Pharmacy
  • 12.5.3. Online Pharmacy
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Drug Class
  • 12.7.2. By Indication
  • 12.7.3. By Distribution Channel
  • 12.7.4. By Country/Sub-region

13. Latin America Cardiovascular Drugs Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Drug Class, 2017-2031
  • 13.3.1. Renin-Angiotensin System Blockers
    • 13.3.1.1. ACE Inhibitors
    • 13.3.1.2. Angiotensin Receptor Blockers
  • 13.3.2. Beta Blockers
  • 13.3.3. Diuretics
  • 13.3.4. Anti-Clotting Agents
    • 13.3.4.1. Anti-Coagulants
    • 13.3.4.2. Platelet Aggregation Inhibitors
  • 13.3.5. Antihyperlipidemics
  • 13.3.6. Other Antihypertensive
  • 13.3.7. Calcium Channel Blockers
  • 13.3.8. Others
• 13.4. Market Value Forecast, by Indication, 2017-2031
  • 13.4.1.1. Hypertension
  • 13.4.1.2. Hyperlipidemia
  • 13.4.1.3. Coronary Artery Disease
  • 13.4.1.4. Peripheral Artery Disease
  • 13.4.1.5. Arrhythmia
  • 13.4.1.6. Others
• 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.5.1. Hospital Pharmacy
  • 13.5.2. Retail Pharmacy
  • 13.5.3. Online Pharmacy
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Drug Class
  • 13.7.2. By Indication
  • 13.7.3. By Distribution Channel
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Drug Class, 2017-2031
  • 14.3.1. Renin-Angiotensin System Blockers
    • 14.3.1.1. ACE Inhibitors
    • 14.3.1.2. Angiotensin Receptor Blockers
  • 14.3.2. Beta Blockers
  • 14.3.3. Diuretics
  • 14.3.4. Anti-Clotting Agents
    • 14.3.4.1. Anti-Coagulants
    • 14.3.4.2. Platelet Aggregation Inhibitors
  • 14.3.5. Antihyperlipidemics
  • 14.3.6. Other Antihypertensive
  • 14.3.7. Calcium Channel Blockers
  • 14.3.8. Others
• 14.4. Market Value Forecast, by Indication, 2017-2031
  • 14.4.1. Hypertension
  • 14.4.2. Hyperlipidemia
  • 14.4.3. Coronary Artery Disease
  • 14.4.4. Peripheral Artery Disease
  • 14.4.5. Arrhythmia
  • 14.4.6. Others
• 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.5.1. Hospital Pharmacy
  • 14.5.2. Retail Pharmacy
  • 14.5.3. Online Pharmacy
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Drug Class
  • 14.7.2. By Indication
  • 14.7.3. By Distribution Channel
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. AstraZeneca
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Pfizer Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Novartis AG
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Merck & Co. Inc.
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Bristol-Myers Squibb Company
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Bayer AG
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Sanofi
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Boehringer Ingelheim GmbH
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview
  • 15.3.9. F. Hoffmann-La Roche Ltd.
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. SWOT Analysis
    • 15.3.9.4. Financial Overview
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Abbott Laboratories
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. SWOT Analysis
    • 15.3.10.4. Financial Overview
    • 15.3.10.5. Strategic Overview
  • 15.3.11. Gilead Sciences, Inc.
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Product Portfolio
    • 15.3.11.3. SWOT Analysis
    • 15.3.11.4. Financial Overview
    • 15.3.11.5. Strategic Overview
  • 15.3.12. Johnson & Johnson
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Product Portfolio
    • 15.3.12.3. SWOT Analysis
    • 15.3.12.4. Financial Overview
    • 15.3.12.5. Strategic Overview
  • 15.3.13. Astellas Pharma, Inc.
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Product Portfolio
    • 15.3.13.3. SWOT Analysis
    • 15.3.13.4. Financial Overview
    • 15.3.13.5. Strategic Overview
  • 15.3.14. Eli Lilly and Company
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Product Portfolio
    • 15.3.14.3. SWOT Analysis
    • 15.3.14.4. Financial Overview
    • 15.3.14.5. Strategic Overview
  • 15.3.15. Otsuka Holdings Co., Ltd.
    • 15.3.15.1. Company Overview
    • 15.3.15.2. Product Portfolio
    • 15.3.15.3. SWOT Analysis
    • 15.3.15.4. Financial Overview
    • 15.3.15.5. Strategic Overview
  • 15.3.16. Takeda Pharmaceuticals Company Ltd.
    • 15.3.16.1. Company Overview
    • 15.3.16.2. Product Portfolio
    • 15.3.16.3. SWOT Analysis
    • 15.3.16.4. Financial Overview
    • 15.3.16.5. Strategic Overview